Patents by Inventor Avner Yayon

Avner Yayon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180127475
    Abstract: The present invention relates to the design, manufacture and use of fibroblast growth factor (FGF) polypeptides having improved receptor specificity. In particular, the invention relates to isolated FGF2 and FGF4 polypeptides comprising a truncated N-terminus and optionally N-terminal amino acid substitutions. The present invention provides polypeptides, nucleic acids encoding the polypeptides, compositions comprising same and methods for use thereof.
    Type: Application
    Filed: December 12, 2017
    Publication date: May 10, 2018
    Applicants: PROCHON BIOTECH LTD., HEPACORE LTD.
    Inventors: Avner Yayon, Eran Rom, Irina Chumakov, Sara Blumenstein
  • Patent number: 9862753
    Abstract: The present invention relates to the design, manufacture and use of fibroblast growth factor (FGF) polypeptides having improved receptor specificity. In particular, the invention relates to isolated FGF2 polypeptides comprising a truncated N-terminus and optionally N-terminal amino acid substitutions. The present invention provides polypeptides, nucleic acids encoding the polypeptides, compositions comprising same and methods for use thereof.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: January 9, 2018
    Assignees: PROCHON BIOTECH LTD., HEPACORE LTD
    Inventors: Avner Yayon, Eran Rom, Irina Chumakov, Sara Blumenstein
  • Publication number: 20170196986
    Abstract: Conjugates of hydrophilic carboxy polysaccharides with protein members of the fibroblast growth factor (FGF) family and variants thereof. The conjugates provide a modified bioactivity and stability of FGFs for various therapeutic applications.
    Type: Application
    Filed: March 21, 2017
    Publication date: July 13, 2017
    Applicant: HEPACORE LTD.
    Inventors: Avner YAYON, Roy SIRKIS, Boaz AMIT, Avraham WORTZEL
  • Publication number: 20170095533
    Abstract: A method of treating an individual (i) having abnormal bone; or (ii) afflicted with a disease or disorder related to normal or abnormal FGF receptors or a skeletal disorder; or (iii) having dysplasic bone. The method includes administering to the individual a pharmaceutical composition comprising a therapeutically effective amount of a fibroblast growth factor 9 (FGF-9) variant comprising at least one amino acid substitution in the beta 8-beta 9 loop, wherein said FGF-9 variant incorporates one of the amino acid sequences set forth in SEQ ID NO: 11, 13, 14, 15, 16 or 17.
    Type: Application
    Filed: November 7, 2016
    Publication date: April 6, 2017
    Inventors: Oren Bogin, Avner Yayon
  • Patent number: 9610357
    Abstract: Conjugates of hydrophilic carboxy polysaccharides with protein members of the fibroblast growth factor (FGF) family and variants thereof. The conjugates provide a modified bioactivity and stability of FGFs for various therapeutic applications.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: April 4, 2017
    Assignee: HEPACORE LTD.
    Inventors: Avner Yayon, Roy Sirkis, Boaz Amit, Avraham Wortzel
  • Patent number: 9487568
    Abstract: A method of treating an individual (i) having abnormal bone; or (ii) afflicted with a disease or disorder related to normal or abnormal FGF receptors or a skeletal disorder; or (iii) having dysplasic bone. The method includes administering to the individual a pharmaceutical composition comprising a therapeutically effective amount of a fibroblast growth factor 9 (FGF-9) variant comprising at least one amino acid substitution in the beta 8-beta 9 loop, wherein said FGF-9 variant incorporates one of the amino acid sequences set forth in SEQ ID NO: 11, 13, 14, 15, 16 or 17.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: November 8, 2016
    Assignee: PROCHON BIOTECH LTD.
    Inventors: Oren Bogin, Avner Yayon
  • Patent number: 9226949
    Abstract: The present invention relates to fibroblast growth factor 18 (FGF-18) variants having various truncations beyond the signal peptide domain of the N-terminus, which activate FGFR3 with increased specificity. The invention further relates to polynucleotides encoding the variants, pharmaceutical compositions comprising same and methods for use thereof in treating cartilage and skeletal disorders.
    Type: Grant
    Filed: March 21, 2013
    Date of Patent: January 5, 2016
    Assignee: HEPACORE LTD.
    Inventors: Avner Yayon, Eran Rom, Roy Sirkis, Dalit Strauss-Ayali
  • Publication number: 20150322126
    Abstract: The present invention relates to the design, manufacture and use of fibroblast growth factor (FGF) polypeptides having improved receptor specificity. In particular, the invention relates to isolated FGF2 and FGF4 polypeptides comprising a truncated N-terminus and optionally N-terminal amino acid substitutions. The present invention provides polypeptides, nucleic acids encoding the polypeptides, compositions comprising same and methods for use thereof.
    Type: Application
    Filed: February 23, 2015
    Publication date: November 12, 2015
    Inventors: Avner Yayon, Eran Rom, Irina Chumakov, Sara Blumenstein
  • Publication number: 20150072426
    Abstract: A method of treating an individual (i) having abnormal bone; or (ii) afflicted with a disease or disorder related to normal or abnormal FGF receptors or a skeletal disorder; or (iii) having dysplasic bone. The method includes administering to the individual a pharmaceutical composition comprising a therapeutically effective amount of a fibroblast growth factor 9 (FGF-9) variant comprising at least one amino acid substitution in the beta 8-beta 9 loop, wherein said FGF-9 variant incorporates one of the amino acid sequences set forth in SEQ ID NO: 11, 13, 14, 15, 16 or 17.
    Type: Application
    Filed: November 19, 2014
    Publication date: March 12, 2015
    Inventors: Oren Bogin, Avner Yayon
  • Patent number: 8962556
    Abstract: The present invention relates to the design, manufacture and use of fibroblast growth factor (FGF) polypeptides having improved receptor specificity. In particular, the invention relates to isolated FGF2 and FGF4 polypeptides that include a truncated N-terminus and optionally N-terminal amino acid substitutions. The present invention provides polypeptides, nucleic acids encoding the polypeptides, compositions of the same and methods for use thereof.
    Type: Grant
    Filed: October 7, 2007
    Date of Patent: February 24, 2015
    Assignee: Prochon Biotech Ltd.
    Inventors: Avner Yayon, Eran Rom, Irina Chumakov, Sara Blumenstein
  • Patent number: 8940888
    Abstract: Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: January 27, 2015
    Assignee: Prochon Biotech Ltd.
    Inventors: Boaz Amit, Avraham Wortzel, Avner Yayon
  • Patent number: 8916522
    Abstract: A method of treating an individual (i) having abnormal bone; or (ii) afflicted with a disease or disorder related to normal or abnormal FGF receptors or a skeletal disorder; or (iii) having dysplasic bone. The method includes administering to the individual a pharmaceutical composition comprising a therapeutically effective amount of a fibroblast growth factor 9 (FGF-9) variant comprising at least one amino acid substitution in the beta 8-beta 9 loop, wherein the FGF-9 variant incorporates one of the amino acid sequences set forth in SEQ ID NO: 11, 13, 14, 15, 16 or 17.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: December 23, 2014
    Assignee: ProChon Biotech Ltd.
    Inventors: Oren Bogin, Avner Yayon
  • Publication number: 20140271868
    Abstract: The present invention relates to a method for the treatment of skeletal dysplasia by administering to a patient a composition comprising a therapeutically effective amount of at least one C-type natriuretic peptide (CNP).
    Type: Application
    Filed: April 17, 2014
    Publication date: September 18, 2014
    Applicant: HEPACORE LIMITED
    Inventors: Myriam Golembo, Avner Yayon
  • Patent number: 8828385
    Abstract: Molecules comprising the antigen-binding portion of antibodies that block constitutive and/or ligand-dependent activation of a receptor protein tyrosine kinase, such as fibroblast growth factor receptor 3 (FGFR3), are found through screening methods, where a soluble dimeric form of a receptor protein tyrosine kinase is used as target for screening a library of antibody fragments displayed on the surface of bacteriophage. The molecules of the present invention which block constitutive activation can be administered to treat or inhibit skeletal dysplasia, craniosynostosis disorders, cell proliferative diseases or disorders, or tumor progression associated with the constitutive activation of a receptor protein tyrosine kinase.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: September 9, 2014
    Assignee: Fibron Limited
    Inventors: Avner Yayon, Eran Rom, Elisabeth Thomassen-Wolf, Eric Borges
  • Publication number: 20140038892
    Abstract: Conjugates of hydrophilic carboxy polysaccharides with protein members of the fibroblast growth factor (FGF) family and variants thereof. The conjugates provide a modified bioactivity and stability of FGFs for various therapeutic applications.
    Type: Application
    Filed: October 15, 2013
    Publication date: February 6, 2014
    Inventors: Avner Yayon, Roy Sirkis, Boaz Amit, Avraham Wortzel
  • Publication number: 20140005141
    Abstract: Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives.
    Type: Application
    Filed: August 29, 2013
    Publication date: January 2, 2014
    Applicants: Bio-Technology General (Israel) Ltd., Prochon Biotech Ltd.
    Inventors: Boaz AMIT, Avraham Wortzel, Avner YAYON
  • Patent number: 8618258
    Abstract: Methods for treating diseased or injured tissue by implanting into the tissue at a site of the disease or injury a porous freeze-dried fibrin matrix formed from plasma proteins. The proteins include fibrinogen cleaved by the action of thrombin at varying concentrations sufficient to cleave the fibrinogen and Factor XIII. The matrix has less than 10% residual moisture and is devoid of exogenous anti-fibrinolytic agents, plasminogen and of organic chelating agents. Alternatively, the plasma proteins comprise partially purified plasma proteins that are devoid of plasminogen.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: December 31, 2013
    Assignee: Prochon Biotech Ltd.
    Inventors: Avner Yayon, Malkit Azachi, Micha Gladnikoff
  • Publication number: 20130338070
    Abstract: A method of treating an individual (i) having abnormal bone; or (ii) afflicted with a disease or disorder related to normal or abnormal FGF receptors or a skeletal disorder; or (iii) having dysplasic bone. The method includes administering to the individual a pharmaceutical composition comprising a therapeutically effective amount of a fibroblast growth factor 9 (FGF-9) variant comprising at least one amino acid substitution in the beta 8-beta 9 loop, wherein said FGF-9 variant incorporates one of the amino acid sequences set forth in SEQ ID NO: 11, 13, 14, 15, 16 or 17.
    Type: Application
    Filed: July 30, 2013
    Publication date: December 19, 2013
    Applicant: ProChon Biotech, Ltd.
    Inventors: Oren BOGIN, Avner YAYON
  • Patent number: 8609823
    Abstract: The present invention provides fibroblast growth factor variants demonstrating enhanced receptor subtype specificity and/or affinity. Preferred embodiments include both variants having enhanced activity that act as improved agonists and variants having reduced activity that act as antagonists. Methods of utilizing preferred FGF variants in preparation of medicaments for the treatment of skeletal disorders including skeletal dysplasia, osteoporosis and enhancing bone fracture healing and cartilage healing processes are provided.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: December 17, 2013
    Assignee: ProChon Biotech, Ltd.
    Inventors: Oren Bogin, Avner Yayon
  • Patent number: 8524885
    Abstract: Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives.
    Type: Grant
    Filed: March 6, 2007
    Date of Patent: September 3, 2013
    Assignees: Prochon Biotech Ltd., Bio-Technology General (Israel) Ltd.
    Inventors: Boaz Amit, Avraham Wortzel, Avner Yayon